The U.S. Food and Drug Administration (FDA) has issued an alert about a serious side effect with Rituxan (rituximab; manufactured by Genentech, Inc.) off-label (not approved by the FDA) in patients with systemic lupus erythematosus (SLE) receiving Rituxan. Rituxan is currently approved by the FDA for treating non-Hodgkin’s lymphoma and refractory rheumatoid arthritis (RA) that does not respond to other RA treatments. (More …)
Latest Tips RSS
-
TargetingTumors.com
-
TargetingTumors.com
Health Canada has published an advisory on Rituxan for both the public and healthcare professionals warning them of the risk of bowel obstruction and GI perforation with Rituxan (rituximab, made by Genentech), even though a clear link has not yet been established. (More …)